Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis
Junchao Cai, … , Jueheng Wu, Mengfeng Li
Junchao Cai, … , Jueheng Wu, Mengfeng Li
Published January 16, 2013
Citation Information: J Clin Invest. 2013;123(2):566-579. https://doi.org/10.1172/JCI65871.
View: Text | PDF
Research Article Oncology

MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis

  • Text
  • PDF
Abstract

Tumor metastasis involves a series of biological steps during which the tumor cells acquire the ability to invade surrounding tissues and survive outside the original tumor site. During the early stages, the cancer cells undergo an epithelial-mesenchymal transition (EMT). Wnt/β-catenin signaling is known to drive EMT and metastasis. Here we report that Wnt/β-catenin signaling is hyperactivated in metastatic breast cancer cells that express microRNA 374a (miR-374a). In breast cancer cell lines, ectopic overexpression of miR-374a promoted EMT and metastasis both in vitro and in vivo. Furthermore, miR-374a directly targeted and suppressed multiple negative regulators of the Wnt/β-catenin signaling cascade, including WIF1, PTEN, and WNT5A. Notably, miR-374a was markedly upregulated in primary tumor samples from patients with distant metastases and was associated with poor metastasis-free survival. These results demonstrate that miR-374a maintains constitutively activated Wnt/β-catenin signaling and may represent a therapeutic target for early metastatic breast cancer.

Authors

Junchao Cai, Hongyu Guan, Lishan Fang, Yi Yang, Xun Zhu, Jie Yuan, Jueheng Wu, Mengfeng Li

×

Figure 7

Clinical association of miR-374a with metastasis of human breast cancer.

Options: View larger image (or click on image) Download as PowerPoint
Clinical association of miR-374a with metastasis of human breast cancer....
(A) Real-time RT-PCR analysis of the expression levels of miR-374a in tumors with metastatic relapse (n = 33) and in tumors without metastasis (n = 133). (B) Kaplan-Meier metastasis-free survival curve comparing 2 groups of high (greater than the mean; n = 48) and low (less than the mean; n = 116) miR-374a expression level in the primary tumors of 166 breast cancer patients; P value is based on a log-rank test. (C) Expression of miR-374a is associated with WIF1, PTEN, WNT5A, E-cadherin, and N-cadherin expression levels and β-catenin localization in clinical breast cancer specimens. Two representative cases are shown. Original magnification, ×400. (D) Percentage of specimens showing low or high miR-374a expression in relation to the expression levels of WIF1, PTEN, WNT5A, E-cadherin, N-cadherin, and cytoplasmic/nuclear or membrane of β-catenin. *P < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts